BUZZ-Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone
Reuters · 2d ago
Share
Listen to the news
** Shares of cancer drug developer Iteos Therapeutics ITOS.O rise 14.7% at $19.16 premarket
** Co says its lung cancer drug, belrestotug, in combination with GSK's GSK.L drug, dostarlimab, showed reduction or disappearance of tumor in 63.3%-76.7% patients, vs 37.5% in patients given only GSK's drug
** GSK's cancer drug dostarlimab is sold under the brand name Jemperli
** The combo was tested in patients with an advanced kind of lung cancer called non-small cell lung cancer
** Stock up 52.5% YTD, as of last close
(Reporting by Kashish Tandon in Bengaluru)
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2024 Webull. All Rights Reserved